ABL teams up with Expression Therapeutics on a hemophilia treatment

Maryland CRO ABL has signed a deal with Expression Therapeutics to to handle cell line development studies and help the biotech produce a treatment for hemophilia A. The candidate, a recombinant factor VIII replacement therapy, is in preclinical testing, and ABL is on board to conduct optimization studies to support large-scale manufacturing of Expression's drug, paving the way for human trials. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.